Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to help HIV/TB patients kick the habit

NCT ID NCT05842161

Symptom relief Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study is testing a new program called QUIT-AD to help people living with HIV or tuberculosis (TB) in Cape Town, South Africa, quit smoking. The program combines proven methods to support smoking cessation and improve HIV/TB treatment results. Researchers will enroll 86 daily smokers to see if the program is practical, well-liked, and effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 83 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 or older 2. Willing and able to provide written informed consent 3. Living with HIV, confirmed via medical record, and history of taking ART for at least three months (consecutively or non-consecutively) 4. Within 4 months of initiating or reinitiating TB treatment; positive GeneXpert test or sputum culture 5. Habitual smoker operationalized as smoking at least 4 days a week 6. Motivation (\> 5/10) to quit smoking or \> 24 hour quit past yr 7. Must be living in the catchment area for either the Town Two Clinic or the Michael Mapongwana Community Health Clinic in Khayelitsha Exclusion Criteria: 1. Current interfering untreated/unstable mental health condition (e.g., psychosis, bipolar dx) 2. Current use of non-study pharmacotherapy for smoking cessation, 3. Cognitive Behavioral Therapy for smoking cessation initiated within the past year, 4. Diagnosed with extra-pulmonary or drug resistant (MDR or XDR) TB based upon chart review

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease Smoking Cessation tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV infections Smoking cessation Tuberculosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Cape Town

    RECRUITING

    Rondebosch, 7700, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.